CTRI/2021/04/032620已完成1 期
Standardization and Single Arm Clinical Trial of AMLAVETAS (Garciniapedunculata Roxb.) to assess its BHEDAN KARMA (AGRYA- Dravya of choice)in PITTASHAYASTHA ASHMARI (Silent Cholelithiasis)
Vd Neha Shivde0 个研究点目标入组 8 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Volunteers with SILENT Gall Calculi.
- •2. Acute cholecystitis with Gall bladder calculi; subsided with conservative
- •management and Patient not willing for surgery.
- •3. Gall Calculi of size < 15mm, single or multiple.
- •4. Patients of Cholelithiasis undergo any type of treatment with no or suboptimal relief.
排除标准
- •1. Individuals having Gall bladder Calculi with any acute conditions.
- •2. Individuals having multiple Gall bladder Calculi more than Five.
- •3. Individuals having Gall bladder Calculi near bile duct.
- •4. Pregnancy.
- •5. Individuals with major systemic illness e.g. Carcinoma, AIDS, TB, DM.
- •6. Gall bladder calculi adhered to the wall of Gall bladder.
研究者
相似试验
进行中（未招募）
不适用
Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.Male and female patients with Parkinson´s disease meeting UKPDS criteriaMedDRA version: 12.1Level: LLTClassification code 10013113Term: Disease Parkinson'sEUCTR2009-017416-33-DEClinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
进行中（未招募）
不适用
An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma - MAGE3-AS15-MEL-001 (MET)EUCTR2008-004007-64-DEGlaxoSmithKline Biologicals115
进行中（未招募）
1 期
An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma - MAGE3-AS15-MEL-001 (MET)First-line treatment for patients with unresectable, MAGE-A3-positive stage III or stage IVa melanomaEUCTR2008-004007-64-FIGlaxoSmithKline Biologicals125
进行中（未招募）
不适用
A study to test the benefit of a new anti-cancer Treatment in patients with unresectable advanced melanomaFirst-line treatment for patients with unresectable, MAGE-A3-positive stage III or stage IVa melanomaMedDRA version: 14.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2008-004007-64-ITGlaxoSmithKline Biologicals115
进行中（未招募）
不适用
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced MelanomaEUCTR2008-004007-64-IEGlaxoSmithKline Biologicals115